{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:42:44Z","timestamp":1790772164569,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014834","name":"Distretto Tecnologico Aerospaziale della Campania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jid.2021.04.031","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:40:38Z","timestamp":1623458438000},"page":"2858-2865.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P.","family":"Werth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-6446","authenticated-orcid":false,"given":"Donna A.","family":"Culton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4421-1147","authenticated-orcid":false,"given":"Josef S.S.","family":"Concha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1907-6692","authenticated-orcid":false,"given":"James S.","family":"Graydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-0672","authenticated-orcid":false,"given":"Laurence J.","family":"Blumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-1602","authenticated-orcid":false,"given":"Joyce","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-6202","authenticated-orcid":false,"given":"Michal","family":"Pyzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4622-825X","authenticated-orcid":false,"given":"Richard S.","family":"Blumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7621-4935","authenticated-orcid":false,"suffix":"III","given":"Russell P.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.04.031_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0190-9622(99)70183-0","article-title":"The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile","volume":"40","author":"Amagai","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.031_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.jid.2021.04.031_bib3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3389\/fimmu.2019.01477","article-title":"Complement activation in autoimmune bullous dermatoses: a comprehensive review","volume":"10","author":"Edwards","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.031_bib4","doi-asserted-by":"crossref","first-page":"e92021","DOI":"10.1172\/jci.insight.92021","article-title":"Setting the target for pemphigus vulgaris therapy","volume":"2","author":"Ellebrecht","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2021.04.031_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.031_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/nyas.13561","article-title":"IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders","volume":"1413","author":"Huijbers","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jid.2021.04.031_bib7","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.04.031_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3181\/00379727-151-39267","article-title":"Serum and blister fluid anticomplementary activity in pemphigus and bullous pemphigoid. Sucrose density gradient studies","volume":"151","author":"Jordon","year":"1976","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jid.2021.04.031_bib9","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2021.04.031_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.031_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/1523-1747.ep12510253","article-title":"Characterization of cryoprecipitates in pemphigus: demonstration of pemphigus antibody activity in cryoprecipitates using the immunofluorescent technique","volume":"69","author":"Miyagawa","year":"1977","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.04.031_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","article-title":"Venous and arterial thrombosis following administration of intravenous immunoglobulins","volume":"16","author":"Paran","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jid.2021.04.031_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2340\/00015555-0249","article-title":"Intravenous immunoglobulin: properties, mode of action and practical use in dermatology","volume":"87","author":"Prins","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.04.031_bib14","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.031_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamadermatol.2013.8175","article-title":"Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score","volume":"150","author":"Rahbar","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.04.031_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fimmu.2015.00357","article-title":"Overexpression of bovine FcRn in mice enhances T-dependent immune responses by amplifying T helper cell frequency and germinal center enlargement in the spleen","volume":"6","author":"Schneider","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.04.031_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2021.04.031_bib18","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.04.031_bib19","first-page":"40","article-title":"C1q binding substances in pemphigus and bullous pemphigoid. Detection with a [131I] C1q binding assay","volume":"28","author":"Tappeiner","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2021.04.031_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4161\/mabs.3.2.14462","article-title":"FcRn overexpression in mice results in potent humoral response against weakly immunogenic antigen","volume":"3","author":"V\u00e9gh","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.jid.2021.04.031_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jop.12913","article-title":"Pemphigus vulgaris disease activity: the role of antibodies to desmogleins and their isotype","volume":"48","author":"Yeoh","year":"2019","journal-title":"J\u00a0Oral Pathol Med"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21013294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21013294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:49:06Z","timestamp":1762206546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21013294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0022202X21013294"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.04.031","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}